CD274 and neoplasm: This study found that neoadjuvant chemoimmunotherapy was superior to neoadjuvant chemotherapy across surgical, pathological, and efficacy outcomes and patients with resectable NSCLC and tumor PD-L1 levels less than 1% had an event-free survival benefit with neoadjuvant chemoimmunotherapy.